Smith & Nephew Spray-On Wound Therapy Misses Leg Ulcer Endpoint
This article was originally published in The Gray Sheet
A phase III study of the firm's live cell spray-on wound therapy (HP802-247) failed, putting the future of the product, acquired by Smith & Nephew in 2012, in question.
You may also be interested in...
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.